Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Summit Therapeutics stock (SMMT)

Buy Summit Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Summit Therapeutics is a biotechnology business based in the US. Summit Therapeutics shares (SMMT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $22.24 – an increase of 11.03% over the previous week. Summit Therapeutics employs 105 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Summit Therapeutics stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Summit Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – SMMT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Summit Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Summit Therapeutics stock price (NASDAQ: SMMT)

Use our graph to track the performance of SMMT stocks over time.

Summit Therapeutics shares at a glance

Information last updated 2024-10-24.
Latest market close$22.24
52-week range$1.64 - $33.89
50-day moving average $18.86
200-day moving average $9.04
Wall St. target price$28.25
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-0.11

Is it a good time to buy Summit Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Summit Therapeutics price performance over time

Historical closes compared with the close of $22.24 from 2024-10-28

1 week (2024-10-22) 8.01%
1 month (2024-09-30) 1.55%
3 months (2024-07-30) 108.04%
6 months (2024-04-30) 465.90%
1 year (2023-10-30) 1,055.32%
2 years (2022-10-28) 1,921.82%
3 years (2021-10-28) 323.62%
5 years (2019-10-30) 1,193.02%

Summit Therapeutics financials

Gross profit TTM $705,000
Return on assets TTM -31.01%
Return on equity TTM -102.77%
Profit margin 0%
Book value $0.27
Market Capitalization $14.7 billion

TTM: trailing 12 months

Summit Therapeutics share dividends

We're not expecting Summit Therapeutics to pay a dividend over the next 12 months.

Have Summit Therapeutics's shares ever split?

Summit Therapeutics's shares were split on 20 September 2020 .

Summit Therapeutics share price volatility

Over the last 12 months, Summit Therapeutics's shares have ranged in value from as little as $1.64 up to $33.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Summit Therapeutics's is -0.974. This would suggest that Summit Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Summit Therapeutics has bucked the trend.

Summit Therapeutics overview

Summit Therapeutics Inc. , a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. .

Frequently asked questions

What percentage of Summit Therapeutics is owned by insiders or institutions?
Currently 84.627% of Summit Therapeutics shares are held by insiders and 10.07% by institutions.
How many people work for Summit Therapeutics?
Latest data suggests 105 work at Summit Therapeutics.
When does the fiscal year end for Summit Therapeutics?
Summit Therapeutics's fiscal year ends in December.
Where is Summit Therapeutics based?
Summit Therapeutics's address is: 601 Brickell Key Drive, Miami, FL, United States, 33131
What is Summit Therapeutics's ISIN number?
Summit Therapeutics's international securities identification number is: US86627T1088
What is Summit Therapeutics's CUSIP number?
Summit Therapeutics's Committee on Uniform Securities Identification Procedures number is: 86627R102

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site